Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05482464 · ClinicalTrials.gov registry record · NA
Effect of Daily Consumption of Glycomacropeptide on Gut Microbiome and Blood Functional Proteome of Subjects With Irritable Bowel Syndrome
A NA study of Inflammatory Bowel Syndrome, sponsored by Oregon State University.
- Completed
- Registry status
- NA
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT05482464: Completed NA study of Inflammatory Bowel Syndrome, sponsored by Oregon State University.
NCT05482464 is a NA study of Inflammatory Bowel Syndrome that has completed, run by Oregon State University. The registered enrollment target is 15 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05482464, a NA study of Inflammatory Bowel Syndrome, has completed, sponsored by Oregon State University.
- COMPLETED
- Registry status
- NA
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
This study investigates the use of glycomacropeptide (GMP) as a means to manipulate the gut microbiome, metabolome and protein profile of subjects with irritable bowel syndrome (IBS).
Primary Outcome
Change in levels of inflammatory markers (GM-CSF, IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12 (p70), IL-13, IL-15, IL-17A, IL-17F, IL-17E/IL-25, IL-21, IL-22, IL-23, IL-27, IL-28A, IL-31, IL-33, MIP-3α/CCL20, TNF-α and TNFβ) in stool and blood using immunology multiplex assay
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Casein glycomacropeptide (CGMP)
Study Locations (1)
Oregon
- Milam Hall, Room 001 - Corvallis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2022-01-01 |
| Est. Completion | 2024-09-01 |
| Phase | NA |
What the finished NCT05482464 record still lists
NCT05482464 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Inflammatory Bowel Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Casein glycomacropeptide (CGMP) is the first listed.
NCT05482464 reports a single indexed study location in Oregon.
Frequently Asked Questions
What is clinical trial NCT05482464 about?
NCT05482464 is a clinical study titled "Effect of Daily Consumption of Glycomacropeptide on Gut Microbiome and Blood Functional Proteome of Subjects With Irritable Bowel Syndrome". This study investigates the use of glycomacropeptide (GMP) as a means to manipulate the gut microbiome, metabolome and protein profile of subjects with irritable bowel syndrome (IBS).
What is the current status of trial NCT05482464?
This trial is currently completed. It is a NA study. The enrollment target is 15 participants. The study started on 2022-01-01. Estimated completion is 2024-09-01.
What conditions does trial NCT05482464 study?
This clinical trial studies the following conditions: Inflammatory Bowel Syndrome.
What interventions are being tested in trial NCT05482464?
The interventions under investigation include: Casein glycomacropeptide (CGMP) (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT05482464?
This trial is sponsored by Oregon State University, which has 33 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05482464 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Inflammatory Bowel Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05482464's enrollment target sits among peer trials
15 1881st of 2000 higher than 92 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI